{
    "organizations": [],
    "uuid": "b39241037fe6780217b3de117b14a3619d33dd46",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/29/pr-newswire-tapimmune-to-provide-fourth-quarter-and-full-year-2017-business-update-conference-call-and-webcast.html",
    "ord_in_thread": 0,
    "title": "TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "JACKSONVILLE, Fla., March 29, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV ), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that the Company will host a conference call and live audio webcast on Thursday, April 5, 2018, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2017.\nReserve Your Seat: Register Today\nThe event will be webcast live via the Internet on:\nApril 5, 2018\n4:30 PM ET\nClick here to register today, or visit https://tapimmune.com/register\nDay-of Call-in Information:\nTo access the live conference call on April 5, 2018, at 4:30pm ET you may use:\n(855) 238-2333 (U.S.) (412) 317-5215 (International)\nTo access the live audio webcast, visit the Events section of the TapImmune website: http://tapimmune.com/events . The webcast will also be archived for 90 days beginning at approximately 6:30 p.m. ET, on April 5, 2018.\nAbout TapImmune Inc.\nTapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be used without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.\nFor additional information visit: https://tapimmune.com/\nTo receive future press releases via email, please visit:\nhttps://tapimmune.com/investors/email-alerts/\nFollow us on Twitter @Tapimmune_Inc , or follow us on Facebook .\nFor answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/\nView original content with multimedia: http://www.prnewswire.com/news-releases/tapimmune-to-provide-fourth-quarter-and-full-year-2017-business-update-conference-call-and-webcast-300621358.html\nSOURCE TapImmune Inc.",
    "published": "2018-03-29T14:30:00.000+03:00",
    "crawled": "2018-03-29T14:08:03.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jacksonville",
        "march",
        "tapimmune",
        "nasdaq",
        "tpiv",
        "leading",
        "company",
        "ongoing",
        "clinical",
        "trial",
        "ovarian",
        "breast",
        "cancer",
        "today",
        "announced",
        "company",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "thursday",
        "april",
        "et",
        "provide",
        "corporate",
        "clinical",
        "update",
        "fourth",
        "quarter",
        "year",
        "end",
        "reserve",
        "seat",
        "register",
        "today",
        "event",
        "webcast",
        "live",
        "via",
        "internet",
        "april",
        "pm",
        "et",
        "click",
        "register",
        "today",
        "visit",
        "http",
        "information",
        "access",
        "live",
        "conference",
        "call",
        "april",
        "et",
        "may",
        "use",
        "international",
        "access",
        "live",
        "audio",
        "webcast",
        "visit",
        "event",
        "section",
        "tapimmune",
        "website",
        "http",
        "webcast",
        "also",
        "archived",
        "day",
        "beginning",
        "approximately",
        "et",
        "april",
        "tapimmune",
        "tapimmune",
        "leader",
        "development",
        "novel",
        "immunotherapy",
        "cancer",
        "multiple",
        "phase",
        "phase",
        "clinical",
        "study",
        "currently",
        "ongoing",
        "treatment",
        "ovarian",
        "breast",
        "cancer",
        "company",
        "peptide",
        "nucleic",
        "immunotherapeutic",
        "product",
        "comprise",
        "multiple",
        "naturally",
        "processed",
        "epitope",
        "npes",
        "designed",
        "comprehensively",
        "stimulate",
        "patient",
        "killer",
        "helper",
        "restore",
        "augment",
        "antigen",
        "presentation",
        "using",
        "proprietary",
        "nucleic",
        "expression",
        "system",
        "unique",
        "approach",
        "produce",
        "vaccine",
        "candidate",
        "elicit",
        "response",
        "used",
        "without",
        "respect",
        "hla",
        "type",
        "company",
        "technology",
        "may",
        "used",
        "medication",
        "combination",
        "treatment",
        "modality",
        "additional",
        "information",
        "visit",
        "http",
        "receive",
        "future",
        "press",
        "release",
        "via",
        "email",
        "please",
        "visit",
        "http",
        "follow",
        "u",
        "twitter",
        "follow",
        "u",
        "facebook",
        "answer",
        "frequently",
        "asked",
        "question",
        "please",
        "visit",
        "faq",
        "page",
        "http",
        "view",
        "original",
        "content",
        "multimedia",
        "http",
        "source",
        "tapimmune",
        "inc"
    ]
}